Company profile: Basking Biosciences
1.1 - Company Overview
Company description
- Provider of commercialization of technology developed at Duke and Ohio State Universities.
Products and services
🔒
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Basking Biosciences
T3D Therapeutics
HQ: United States
Website
- Description: Provider of remedial therapeutics for Alzheimer's disease and other CNS disorders, including T3D-959, an investigational oral drug candidate designed to treat Alzheimer's by improving brain glucose and lipid metabolism, potentially addressing multiple disease manifestations.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full T3D Therapeutics company profile →
GH Research
HQ: Ireland
Website
- Description: Provider of clinical-stage 5-MeO-DMT (mebufotenin) therapies for psychiatric and neurological disorders, initially focused on treatment-resistant depression: GH001 inhalation (Phase 2b TRD; Phase 2a bipolar II and postpartum depression), GH002 intravenous (completed Phase 1), and GH003 intranasal (preclinical).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full GH Research company profile →
Avalo Therapeutics
HQ: United States
Website
- Description: Provider of clinical-stage biopharmaceutical therapies for immunologic, immuno-oncologic and rare genetic disorders, advancing treatments for rare and orphan diseases. Pipeline includes AVTX-009 (anti-IL-1β) for inflammatory diseases; quisovalimab (anti-LIGHT) for inflammatory conditions; AVTX-008 (BTLA agonist) for immune dysregulation; and AVTX-002 (anti-LIGHT) in Phase 2 for non-eosinophilic asthma, inflammatory bowel diseases, and COVID-19 acute respiratory distress syndrome.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Avalo Therapeutics company profile →
IRLAB Therapeutics
HQ: Sweden
Website
- Description: Provider of drug discovery and development for brain disorders, targeting core dysfunctions in Parkinson’s disease and dementias. Offers ISP, a proprietary systems pharmacology platform built on a unique CNS compound database, and is advancing two phase II candidates: Mesdopetam (IRL790) for levodopa-induced dyskinesia and Pirepemat (IRL752) for impaired balance and reducing falls in Parkinson’s disease.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full IRLAB Therapeutics company profile →
Caraway Therapeutics
HQ: United States
Website
- Description: Provider of precision small-molecule therapeutics for CNS and rare diseases, developing medicines that enhance cellular clearance by activating the lysosome to remove toxic materials and defective cellular components. Leverages modulation of mitophagy and autophagy to use natural clearance pathways, preventing cell damage and treating neurodegenerative disease.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Caraway Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Basking Biosciences
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Basking Biosciences
2.2 - Growth funds investing in similar companies to Basking Biosciences
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Basking Biosciences
4.2 - Public trading comparable groups for Basking Biosciences
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →